Organic Chemistry Division, National Chemical Laboratory, Pune 411 008, India.
Bioorg Med Chem Lett. 2009 Feb 1;19(3):759-63. doi: 10.1016/j.bmcl.2008.12.026. Epub 2008 Dec 10.
Fluconazole based novel mimics containing 1,2,3-triazole were designed and synthesized as antifungal agents. Their antifungal activities were evaluated in vitro by measuring the minimal inhibitory concentrations (MICs). Compounds 12, 15, and 16 were found to be more potent against Candida fungal pathogens than control drugs fluconazole and amphotericin B. The studies presented here provide structural modification of fluconazole to give 1,2,3-trazole containing molecules. Furthermore, these molecules were evaluated in vivo against Candida albicans intravenous challenge in Swiss mice and antiproliferative activities were tested against human hepatocellular carcinoma Hep3B and human epithelial carcinoma A431. It was found that compound 12 resulted in 97.4% reduction in fungal load in mice and did not show any profound proliferative effect at lower dose (0.001 mg/ml).
设计并合成了含有 1,2,3-三唑的基于氟康唑的新型模拟物作为抗真菌药物。通过测量最小抑菌浓度 (MIC),评估了它们在体外的抗真菌活性。化合物 12、15 和 16 对念珠菌真菌病原体的活性比对照药物氟康唑和两性霉素 B 更强。本研究提供了对氟康唑进行结构修饰以得到含 1,2,3-三唑的分子的方法。此外,还在体内针对白色念珠菌静脉内挑战的瑞士小鼠评估了这些分子,并测试了它们对人肝癌 Hep3B 和人上皮癌细胞 A431 的抗增殖活性。结果发现,化合物 12 可使小鼠中的真菌负荷减少 97.4%,并且在较低剂量(0.001mg/ml)下没有显示出任何明显的增殖作用。